The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Probucol Protects Against Adriamycin Cardiomyopathy Without Interfering With Its Antitumor Effect
Abstract
Background The usefulness of adriamycin (ADR), a potent antitumor antibiotic, is limited by the development of life-threatening cardiomyopathy and congestive heart failure. Subcellular changes leading to heart failure are suggested to be mediated by a drug-induced increase in free radicals and lipid peroxidation. In an earlier study, concurrent treatment with probucol (PROB), a lipid-lowering drug with strong antioxidant properties, was shown to offer only partial protection against ADR cardiomyopathy. The present study had two aims: to determine whether this protective effect can be improved further by extended treatment with PROB, and to determine whether PROB affects the antitumor properties of ADR. Methods and Results ADR (cumulative dose, 15 mg/kg body wt) was administered in rats in six equal injections (IP) over a period of 2 weeks. Three weeks after the end of treatment, cardiomyopathy and congestive heart failure were characterized by ascites, congested liver, depressed cardiac function, elevated left ventricular end-diastolic pressure, and myocardial cell damage. Myocardial glutathione peroxidase (GSHPx) activity was decreased and lipid peroxidation was increased. Administration of PROB (cumulative dose, 120 mg/kg body wt) in 12 equal injections (IP), before and concurrent with ADR, completely prevented these cardiomyopathic changes, normalized left ventricular function, lowered mortality, and eliminated ascites. Treatment with PROB was also accompanied by an increase in myocardial GSHPx and superoxide dismutase activities with a concomitant decrease in lipid peroxidation. Tumor regression in syngeneic DBA/2 mice inoculated with L5178Y-F9 lymphoma cells in the ADR+PROB group was significant and comparable to the ADR group. Conclusions These data show for the first time that PROB can provide complete protection against ADR cardiomyopathy without interfering with antitumor properties of the drug. This protective effect of PROB may be related to the maintenance of the antioxidant status of the heart.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331
Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase.
Paglia, D. E., & Valentine, W. N. (1967) · PubMed · Cited by 10,889
Handbook of methods for oxygen radical research
Greenwald, R. A. (1987) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(87)80012-6 · Cited by 2,381
Estimation of product of lipid peroxidation (malonyl dialdehyde) in biochemical systems
Placer, Z. A., Cushman, L. L., & Johnson, B. C. (1966) · Analytical Biochemistry · doi:10.1016/0003-2697(66)90167-9 · Cited by 2,328
A clinicopathologic analysis of adriamycin cardiotoxicity
Lefrak, E. A., Piťha, J., Rosenheim, S., & Gottlieb, J. A. (1973) · Cancer · doi:10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2 · Cited by 1,560
Adriamycin: The Role of Lipid Peroxidation in Cardiac Toxicity and Tumor Response
Myers, C. E., McGuire, W. P., Liss, R. H., Ifrim, I., Grotzinger, K., & Young, R. C. (1977) · Science · doi:10.1126/science.877547 · Cited by 1,111
Cardiac Toxicity 4 to 20 Years After Completing Anthracycline Therapy
Steinherz, L. J. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470120074036 · Cited by 989
Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion
LEGHA, S. S., BENJAMIN, R. S., MACKAY, B., EWER, M., WALLACE, S., VALDIVIESO, M., RASMUSSEN, S. L., BLUMENSCHEIN, G. R., & FREIREICH, E. J. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-2-133 · Cited by 763
Effect of anthracycline antibiotics on oxygen radical formation in rat heart.
Doroshow, J. H. (1983) · PubMed · Cited by 711
Subcellular effects of adriamycin in the heart: A concise review
SINGAL, P., DEALLY, C., & WEINBERG, L. (1987) · Journal of Molecular and Cellular Cardiology · doi:10.1016/s0022-2828(87)80392-9 · Cited by 465
Self-citation
Cited by
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Doxorubicin-Induced Cardiomyopathy
Singal, P. K., & Iliskovic, N. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809243391307 · Cited by 1,845
Self-citationRole of oxidative stress in cardiovascular diseases
Dhalla, N. S., Temsah, R. M., & Netticadan, T. (2000) · Journal of Hypertension · doi:10.1097/00004872-200018060-00002 · Cited by 1,467
Rawat, P. S., Jaiswal, A., Khurana, A., Bhatti, J. S., & Navik, U. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111708 · Cited by 909
Doxorubicin-Induced Cardiomyopathy
Takemura, G., & Fujiwara, H. (2007) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2006.10.002 · Cited by 827
Šimůnek, T., Štěrba, M., Popelová, O., Adamcová, M., Hrdina, R., & Geršl, V. (2009) · Pharmacological Reports · doi:10.1016/s1734-1140(09)70018-0 · Cited by 769
Cardiotoxicity of Chemotherapeutic Agents: Incidence, Treatment and Prevention
Pai, V. B., & Nahata, M. C. (2000) · Drug Safety · doi:10.2165/00002018-200022040-00002 · Cited by 729
Molecular mechanism of doxorubicin-induced cardiomyopathy – An update
Renu, K., V.G., A., P.B., T. P., & Arunachalam, S. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.043 · Cited by 588
Antioxidant potentials of vitamin A and carotenoids and their relevance to heart disease
Palace, V. P., Khaper, N., Qin, Q., & Singal, P. K. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(98)00266-4 · Cited by 482
Self-citationCardiac side-effects of cancer chemotherapy
Monsuez, J.-J., Charniot, J.-C., Vignat, N., & Artigou, J.-Y. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.03.003 · Cited by 467
Yen, H. C., Oberley, T. D., Vichitbandha, S., Ho, Y. S., & St Clair, D. K. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118909 · Cited by 459
Anthracycline Cardiotoxicity: From Bench to Bedside
Gianni, L., Herman, E. H., Lipshultz, S. E., Minotti, G., Sarvazyan, N., & Sawyer, D. B. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9401 · Cited by 454
Wouters, K. A., Kremer, L. C. M., Miller, T. L., Herman, E. H., & Lipshultz, S. E. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05759.x · Cited by 453
Adriamycin-induced heart failure: mechanisms and modulation
Singal, P., Li, T., Kumar, D., Danelisen, I., & Iliskovic, N. (2000) · Molecular and Cellular Biochemistry · doi:10.1023/a:1007094214460 · Cited by 428
Self-citationCardiotoxicity of cytotoxic drugs
Schimmel, K. J. M., Richel, D. J., van den Brink, R. B. A., & Guchelaar, H.-J. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.07.003 · Cited by 391
New insights into doxorubicin-induced cardiotoxicity: The critical role of cellular energetics
Tokarska-Schlattner, M., Zaugg, M., Zuppinger, C., Wallimann, T., & Schlattner, U. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.06.009 · Cited by 350
The role of oxidative stress in the genesis of heart disease
Singal, P. (1998) · Cardiovascular Research · doi:10.1016/s0008-6363(98)00244-2 · Cited by 345
Self-citationWenningmann, N., Knapp, M., Ande, A., Vaidya, T. R., & Ait-Oudhia, S. (2019) · Molecular Pharmacology · doi:10.1124/mol.119.115725 · Cited by 334
NAGI, M. N., & MANSOUR, M. A. (2000) · Pharmacological Research · doi:10.1006/phrs.1999.0585 · Cited by 331
Štěrba, M., Popelová, O., Vávrová, A., Jirkovský, E., Kovaříková, P., Geršl, V., & Šimůnek, T. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4795 · Cited by 329
Free radicals and antioxidants in chemotherapyinduced toxicity
Weijl, N. I., Cleton, F. J., & Osanto, S. (1997) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(97)90012-8 · Cited by 325
Kinugawa, S., Tsutsui, H., Hayashidani, S., Ide, T., Suematsu, N., Satoh, S., Utsumi, H., & Takeshita, A. (2000) · Circulation Research · doi:10.1161/01.res.87.5.392 · Cited by 323
Adriamycin cardiomyopathy: pathophysiology and prevention
Singal, P. K., Iliskovic, N., Li, T., & Kumar, D. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.12.9337145 · Cited by 310
Self-citationAnthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management
Barry, E., Alvarez, J. A., Scully, R. E., Miller, T. L., & Lipshultz, S. E. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.8.1039 · Cited by 307
Losing heart: the role of apoptosis in heart disease—a novel therapeutic target?
Gill, C., Mestril, R., & Samali, A. (2002) · The FASEB Journal · doi:10.1096/fj.01-0629com · Cited by 289
Transcription Factor GATA4 Inhibits Doxorubicin-induced Autophagy and Cardiomyocyte Death
Kobayashi, S., Volden, P., Timm, D., Mao, K., Xu, X., & Liang, Q. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.070037 · Cited by 284
Pacher, P., Liaudet, L., Bai, P., Mabley, J. G., Kaminski, P. M., Virág, L., Deb, A., Szabó, E., Ungvári, Z., Wolin, M. S., et al. (2003) · Circulation · doi:10.1161/01.cir.0000048192.52098.dd · Cited by 279
Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-clinical Therapeutic Approaches
Sheibani, M., Azizi, Y., Shayan, M., Nezamoleslami, S., Eslami, F., Farjoo, M. H., & Dehpour, A. R. (2022) · Cardiovascular Toxicology · doi:10.1007/s12012-022-09721-1 · Cited by 276
Shiomi, T., Tsutsui, H., Matsusaka, H., Murakami, K., Hayashidani, S., Ikeuchi, M., Wen, J., Kubota, T., Utsumi, H., & Takeshita, A. (2004) · Circulation · doi:10.1161/01.cir.0000109701.77059.e9 · Cited by 260
Apoptosis and heart failure: clinical relevance and therapeutic target
GARG, S., NARULA, J., & CHANDRASHEKHAR, Y. (2005) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2004.11.006 · Cited by 103
DeAtley, S. M., Aksenov, M. Y., Aksenova, M. V., Harris, B., Hadley, R., Cole Harper, P., Carney, J. M., & Butterfield, D. A. (1999) · Cancer Letters · doi:10.1016/s0304-3835(98)00306-1 · Cited by 89
Supervised, Individualized Exercise Programs Help Mitigate Costs during Cancer Treatment
Wonders, K. (2018) · Journal of Palliative Care & Medicine · doi:10.4172/2165-7386.1000338 · Cited by 4
Metadata
- Authors
- Siveski-Iliskovic, N., Hill, M., Chow, D. A., & Singal, P. K.
- Venue
- Circulation
- Published
- 1995-01
- Volume
- 91
- Issue
- 1
- Pages
- 10-15
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2011012865
- Cited by
- 285
- References
- 27
- FWCI
- 10.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.